Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST) announced two abstracts accepted for presentation at the 2023 AACR Annual Meeting, scheduled for April 14-19 in Orlando, FL. The posters will cover biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, and preclinical data on the TREX1 inhibitor targeting the STING pathway. The first presentation, focusing on lipid and immune-based biomarkers, will occur on April 17, 2023. The second will discuss novel TREX1 inhibitors also on April 17. Tempest's innovative therapies are designed to treat various tumors through immune-mediated mechanisms, pending FDA approval.

Positive

• Acceptance of two abstracts for presentation at the prestigious 2023 AACR Annual Meeting.
• Showcase of biomarker data from Phase 1 trial of TPST-1120, potentially indicating therapeutic efficacy.
• Advancements in preclinical data for TREX1 inhibitors, showing ongoing innovation in the pipeline.

Negative

• None.

BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator.

Poster presentation details:

Title:	Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha
Session Category:	Clinical Research Excluding Trials
Session Title:	Biomarkers of Therapeutic Benefit 2
Session Date & Time:	Monday, April 17, 2023 9:00 a.m. - 12:30 p.m. ET
Location:	Poster Section 39
Abstract Number:	2130
Title:	Generation of novel potent human TREX1 inhibitors facilitated by crystallography
Session Category:	Experimental and Molecular Therapeutics
Session Title:	Novel Antitumor Agents 3
Session Date & Time:	Monday, April 17, 2023 9:00 a.m. - 12:30 p.m. ET
Location:	Poster Section 17
Abstract Number:	1636

___________________________

¹ If approved by the FDA

Abstracts are available for viewing via the AACR Online Itinerary Planner located here, https://www.abstractsonline.com/pp8/#!/10828.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

What is the significance of the TPST abstracts accepted at the 2023 AACR Annual Meeting?

The TPST abstracts will present critical biomarker data and innovative research on TPST-1120 and TREX1 inhibitors, showcasing potential advancements in oncology therapies.

When will Tempest Therapeutics present at the AACR Annual Meeting?

Tempest Therapeutics will present its abstracts on April 17, 2023.

What does the TPST-1120 trial data indicate?

The trial data focuses on lipid and immune-based biomarkers associated with clinical response, which could inform future treatment strategies.

What is the focus of the TREX1 inhibitor research presented by Tempest?

The TREX1 inhibitor research aims to provide insights into tumor-selective STING pathway activation, which is crucial for immune response in cancer treatment.